EchoGo Amyloidosis vs VitalConnect VitalPatch
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, EchoGo Amyloidosis, is an AI-powered diagnostic screening tool specifically designed for the early detection of cardiac amyloidosis from echocardiogram video clips. In contrast, Tool B, VitalConnect VitalPatch, is a wearable biosensor and cloud platform focused on real-time, continuous monitoring of vital signs and cardiac arrhythmias. While both utilize AI in cardiology, they serve distinct purposes: one for specific disease diagnosis and the other for ongoing physiological surveillance.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is an AI-powered screening tool designed to aid in the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. In contrast, VitalPatch is a wearable biosensor and cloud-based platform for real-time, continuous monitoring of vital signs and cardiac arrhythmias for healthcare professionals, enabling remote patient monitoring and in-hospital care.
EchoGo Amyloidosis analyzes existing echocardiogram video clips using AI to identify suspected cardiac amyloidosis. VitalPatch utilizes a wearable biosensor to continuously stream up to 11 vital signs, including live ECG, and detects 21 cardiac arrhythmias using AI algorithms, with data stored and analyzed on a cloud-based platform.
EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on echocardiographic markers. VitalPatch streams real-time vital signs and live ECG, and offers detection of 21 cardiac arrhythmias through its AI algorithms.
EchoGo Amyloidosis is designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7. VitalPatch uses a cloud-based platform (VitalCloud, VistaCenter) for data storage and analysis, with patient-carried relay devices (VistaPhone/VistaTablet) for data transmission.
For EchoGo Amyloidosis, inpatient analysis is covered by Medicare via NTAP Code ICD-10 XXE2X19 at $1,000 per analysis, and outpatient analysis is covered by Medicare and select commercial insurers via HCPCS Code C9786 at $285 per analysis. VitalPatch services are subscription-based, with monthly fees tied to clinical services, and are widely covered by Medicare and private insurers.
EchoGo Amyloidosis requires no direct patient involvement beyond the standard echocardiogram procedure, as it analyzes existing video clips. VitalPatch requires patients to wear a biosensor for up to 7 days and potentially carry relay devices like a VistaPhone or VistaTablet to ensure continuous data streaming.
EchoGo Amyloidosis demonstrates high diagnostic accuracy with 85% sensitivity and 93% specificity for identifying suspected cardiac amyloidosis. It also shows consistent performance across cardiac amyloidosis subtypes, including AL, wild-type ATTR, and variant ATTR.
More Comparisons
Backers
Who funded each tool's parent company.